Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Council Members who Use the IDI-MRSA assay in the U.S.

Articles with lock require a subscription to GLG News | Request a free trial
October 13, 2008
C. difficile infection not neccesarily related to antibiotics.
Analysis of: C. Difficile And Antibiotics Not Necessarily Linked, Study Finds | www.sciencedaily.com
Author: GLG Expert Contributor
The key point in this article is that the author shows a connection between Community Acquired clostridium difficile infections & lack of antimicrobial use. For example, the widespread use of ant-acids ie; proton pump inhibitors. This article is helpful because delineating some of the risk factors...
July 21, 2008
DRUG VERSES FOOD-IMPORTANCE HOW MD CAN HELP THEIR PATIENT
Analysis of: Patients Curb Prescription Spending | online.wsj.com
Author: GLG Expert Contributor
TODAY MANY PATIENTS HAS DILEMA TO BUY FOOD OR DRUG               EFECTIVENESS OF GENERIC DRUG ALSO MAIL ORDER OR LOCAL PHARMACY COST
July 15, 2008
Medicare - Carrot and the Stick!
Analysis of: Medicare Bil Includes e-Prescribing Bonus | www.modernhealthcare.com
Author: GLG Expert Contributor
Medicare will use a very small carrot to entice financially stressed physicians to employ electronic prescribing technology.  Later on, Medicare will switch to the stick and penalize physicians who don't use such a system.
July 14, 2008
Access to physicians saved...for now!
Analysis of: Bill to Block Medicare-Fee Cuts | online.wsj.com
Author: GLG Expert Contributor
Cuts in Medicare put off for the time being, though only under substantial political pressure.  This band-aid will last only so long; real reform of the flawed sustainable growth rate eludes us yet again!  Bush and friends still favor the insurance lobby over senior's access to their phys...
July 14, 2008
PhRMA wants to have their cake...then eat it too!
Analysis of: Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline | online.wsj.com
Author: GLG Expert Contributor
Drug makers complain that the FDA's 'safety focus' slows down their development of new medications.  They would love to see accelerated approvals; next they'll get the immunity from lawsuits that device makers have already received!
May 22, 2008
Lead In Toys/Contaminated Heparin vs Lower Cost Drugs!
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor
Any finished medication that a Chinese company tries to bring to the US (or European) market will face tremendous scrutiny.  Look for Indian generic manufacturers (e.g. Ranbaxy, Dr Reddy's) to maintain their competitive edge due to their track record of safety.  Eventually, lower cost generics...
May 22, 2008
Beware the Unlicensed Practitioner!
Analysis of: Renal Failure Linked to Cosmetic Soft-Tissue Filler Injections | www.medscape.com
Author: GLG Expert Contributor
These 3 cases add to a number of others which have appeared in the news media, raising public awareness regarding procedures performed by unlicensed practitioners.  Such cases are unlikely to impact the blooming market in FDA-approved fillers when administered by medical professionals.
May 20, 2008
Big Pharma Losing Control
Analysis of: Warning over drug trial’s effects on testing | www.ft.com
Author: GLG Expert Contributor
For too long big pharma has dictated which drugs will come to market and what they will cost.  The entire American healthcare system is literally collapsing because of two costs:  medications and bureacracy.  Expect more payers to look for ways to bring down costs in the fu...
March 27, 2008
DNAi - early stage excitement
Analysis of: Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic | www.pipelinereview.com
Author: GLG Expert Contributor
DNAi technology, as presented by Pronal Therapeutics provides an exciting opportunity to use this technology as a therapeutic.  PNT2258 may be an important nucleic acid in combating certain types of cancer and solid tumor.  It is an important milestone to have FDA acceptance to begin Phase...
February 7, 2008
Botulinum Toxin Type A has long-term efficacy and safety for glabellar skin lines
Analysis of: Efficacy of Botulinum Toxin Does Not Sag Over Time | www.medscape.com
Author: GLG Expert Contributor
The long term efficacy of botulinum toxin Type A for the treatment of glabellar frown lines was recently discussed  in San Antonio, Texas at the 66th annual meeting of the American Association of Dermatology. Kawashima and other fellow Japanese investigators presented long-term (64 weeks)...

Page : 1 2 3 Next1 to 10 of 29

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163